Trial Profile

A pivotal program study of MZE829.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MZE-829 (Primary)
Indications Renal failure
Focus Registrational; Therapeutic Use

Most Recent Events

12 May 2026 According to Maze Therapeutics media release, the trial is anticipated to be initiated in the first half of 2027, subject to regulatory feedback.
12 Apr 2026 New trial record
25 Mar 2026 According to Maze Therapeutics media release, , the Company plans to advance to a pivotal program.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com